Cataract extraction without prophylactic treatment in patients with severe factor XI deficiency

Am J Ophthalmol. 2009 Dec;148(6):920-4.e1. doi: 10.1016/j.ajo.2009.07.013. Epub 2009 Sep 5.

Abstract

Purpose: To assess the risks of intraoperative and postoperative bleeding associated with cataract extraction without prophylactic treatment in patients with severe factor XI (FXI) deficiency.

Design: Prospective interventional case series.

Setting: Single institute.

Study population: Consecutive unrelated patients with severe FXI deficiency who underwent cataract extraction under topical anesthesia, with a clear corneal incision, phacoemulsification, and implantation of a foldable posterior chamber intraocular lens (PCIOL) were enrolled. Patients with associated intraocular conditions that could complicate the surgery were excluded.

Intervention: Cataract extraction without prophylactic treatment for the FXI deficiency.

Main outcome measures: Assessment of intraoperative and postoperative ocular bleeding and other related complications.

Results: Seven patients ranging in age from 61 to 95 years (median, 79) underwent phacoemulsification and PCIOL implantation in 11 eyes. Five patients (71%) were homozygotes for type II mutation of the FXI gene (activity level of <1 U/dl), 1 patient was a homozygote for type III mutation (activity level of 11 U/dl), and 1 patient was a compound heterozygote for types II and III (activity level of 3 U/dl). Three of the patients (43%), all type II homozygotes, also had an inhibitor antibody to FXI. All 7 patients were followed for at least 1 week after the operation. The surgery was uneventful in all eyes, and neither major nor minor bleeding events were observed in any of the operated eyes during surgery and follow-up.

Conclusions: Cataract extraction by phacoemulsification in uncomplicated eyes can be performed safely without prophylactic treatment in patients with severe FXI deficiency with or without inhibitor antibodies against FXI.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Blood Loss, Surgical / prevention & control*
  • Eye Hemorrhage / prevention & control*
  • Factor XI / genetics
  • Factor XI / immunology
  • Factor XI Deficiency / surgery*
  • Female
  • Humans
  • Lens Implantation, Intraocular*
  • Male
  • Middle Aged
  • Phacoemulsification*
  • Polymerase Chain Reaction
  • Postoperative Hemorrhage / prevention & control*
  • Prospective Studies
  • Prothrombin Time
  • Risk Assessment

Substances

  • Factor XI